Published online Nov 26, 2024. doi: 10.4330/wjc.v16.i11.665
Revised: October 14, 2024
Accepted: October 23, 2024
Published online: November 26, 2024
Processing time: 67 Days and 10.7 Hours
Sodium-dependent glucose transporter 2 inhibitors (SGLT2i) have been increa
Core Tip: Grubić Rotkvić et al published an observational study on the use of sodium-dependent glucose transporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus and asymptomatic heart failure. Their findings included reduced cardiac load and improved cardiovascular performance related to the use of SGLT2i. This suggests that SGLT2i are not merely glucose-lowering drugs; they are integral to the broader cardiovascular management in patients with type 2 diabetes mellitus.
- Citation: Laimoud MH, Raslan IR. Effects of sodium-dependent glucose transporter 2 inhibitors in patients with type 2 diabetes mellitus and asymptomatic heart failure. World J Cardiol 2024; 16(11): 665-668
- URL: https://www.wjgnet.com/1949-8462/full/v16/i11/665.htm
- DOI: https://dx.doi.org/10.4330/wjc.v16.i11.665
The expanding interest in sodium-dependent glucose transporter 2 inhibitors (SGLT2i) as a cornerstone therapy in the management of heart failure (HF) has significantly impacted contemporary cardiology. A recent observational study by Grubić Rotkvić et al[1] provides crucial insights into the utility of SGLT2i in patients with type 2 diabetes mellitus (T2DM) who exhibit asymptomatic HF. Their study builds on previous data by focusing on the mechanisms underlying the car
This prospective observational study evaluated a cohort of patients with T2DM receiving dual antidiabetic therapy, including metformin and either SGLT2i or dipeptidyl peptidase-4 inhibitors. The study divided treatment arms into two subgroups based on baseline parameters such as high-sensitivity C-reactive protein, myeloperoxidase, global longitudinal strain (GLS), N-terminal pro-brain natriuretic peptide, and systolic and diastolic blood pressures.
The results indicated that SGLT2i therapy led to a significant reduction in oxidative stress and inflammatory markers, particularly myeloperoxidase and high-sensitivity C-reactive protein, especially in patients with elevated baseline levels of these biomarkers. This aligns with evidence highlighting the anti-oxidative and anti-inflammatory properties of SGLT2i, contributing to their cardiovascular benefits[2,3]. Notably, there was a greater reduction in the studied variables in the patients with high baseline values, irrespective of the treatment group, after follow-up.
Recent meta-analyses have underscored the multifaceted benefits of SGLT2i beyond glycemic control. SGLT2i have consistently demonstrated a significant reduction in HF hospitalisation and cardiovascular mortality across various populations, including patients with and without T2DM. These outcomes were particularly pronounced in patients with HF and reduced ejection fraction[4,5]. SGLT2i received a class IA recommendation for treatment of patients with HF and reduced ejection fraction, regardless of diabetes mellitus status, according to the American College of Cardiology and American Heart Association and guidelines[6,7]. The EMPULES trial is a multicentre international double-blind, clinical trial that randomised 530 patients with acute HF to receive empagliflozin or a placebo. The trial reported decreased mortality and HF-related hospitalisations during the 90-day follow-up, regardless of left ventricular ejection fraction and diabetes status[8]. The recent European Society of Cardiology recommended the use of SGLT2i as a class IA treatment for patients with HF and left ventricular ejection fraction (> 40%) to reduce HF-related hospitalisation and cardiovascular mortality[9]. Further, SGLT2i also demonstrated efficacy in patients with HF with preserved ejection fraction. The EMPEROR-Preserved trial and subsequent meta-analyses revealed a reduction in HF-related hospitalisations or car
The protective cardiovascular effects of SGLT2i are attributed to several mechanisms, including osmotic diuresis, which leads to volume reduction, decreased blood pressure, and improved ventricular loading conditions. Additionally, SGLT2i reduce myocardial fibrosis, oxidative stress, and sympathetic nervous system activation, all of which are critical in HF pathophysiology[2]. Moreover, SGLT2i provide substantial renoprotective effects, particularly in patients with T2DM. They reduce the risk of adverse renal outcomes, likely by modulating intraglomerular pressure and reducing hyper
The study by Grubić Rotkvić et al[1] provides a nuanced understanding of the cardiometabolic benefits of SGLT2i, particularly in the early stages of HF. The observation that SGLT2i improve GLS and attenuates sympathetic nervous system activation without significantly lowering N-terminal pro-brain natriuretic peptide levels suggests that SGLT2i may exert their cardioprotective effects through mechanisms independent of natriuretic peptide modulation. The improvement in myocardial function, as evidenced by enhanced GLS and reduced oxidative stress, underscores the potential of SGLT2i in preventing the progression from asymptomatic to symptomatic HF in patients with diabetes[15,16].
However, the study also has limitations including the small sample size and short follow-up period, which may pre
The findings of the study by Grubić Rotkvić et al[1] reinforce the evolving paradigm that SGLT2i are not merely glucose-lowering agents but are integral to the broader management of cardiovascular risk in patients with T2DM. The study contributes to the growing literature supporting the early use of SGLT2i in diabetic cardiomyopathy, offering a potential strategy to mitigate the progression of HF. Future large studies should be conducted to confirm these findings and explore the long-term cardiovascular benefits of SGLT2i, particularly in asymptomatic patients at a risk of developing HF.
1. | Grubić Rotkvić P, Rotkvić L, Đuzel Čokljat A, Cigrovski Berković M. Sodium-dependent glucose transporter 2 inhibitors effects on myocardial function in patients with type 2 diabetes and asymptomatic heart failure. World J Cardiol. 2024;16:448-457. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited in This Article: ] [Reference Citation Analysis (0)] |
2. | Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61:2108-2117. [RCA] [PubMed] [DOI] [Full Text] [Cited in This Article: ] [Cited by in Crossref: 513] [Cited by in RCA: 640] [Article Influence: 91.4] [Reference Citation Analysis (0)] |
3. | Kaze AD, Zhuo M, Kim SC, Patorno E, Paik JM. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis. Cardiovasc Diabetol. 2022;21:47. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited in This Article: ] [Cited by in Crossref: 58] [Cited by in RCA: 58] [Article Influence: 19.3] [Reference Citation Analysis (0)] |
4. | Cleland JGF. Nature and Magnitude of the Benefits of Dapagliflozin and Empagliflozin for Heart Failure. Circulation. 2024;149:839-842. [RCA] [PubMed] [DOI] [Full Text] [Cited in This Article: ] [Reference Citation Analysis (0)] |
5. | Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F; EMPEROR-Reduced Trial Investigators. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383:1413-1424. [RCA] [PubMed] [DOI] [Full Text] [Cited in This Article: ] [Cited by in Crossref: 1875] [Cited by in RCA: 2970] [Article Influence: 594.0] [Reference Citation Analysis (0)] |
6. | Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79:e263-e421. [RCA] [PubMed] [DOI] [Full Text] [Cited in This Article: ] [Cited by in Crossref: 70] [Cited by in RCA: 1160] [Article Influence: 386.7] [Reference Citation Analysis (0)] |
7. | Maddox TM, Januzzi JL Jr, Allen LA, Breathett K, Brouse S, Butler J, Davis LL, Fonarow GC, Ibrahim NE, Lindenfeld J, Masoudi FA, Motiwala SR, Oliveros E, Walsh MN, Wasserman A, Yancy CW, Youmans QR. 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2024;83:1444-1488. [RCA] [PubMed] [DOI] [Full Text] [Cited in This Article: ] [Reference Citation Analysis (0)] |
8. | Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Piña IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M; EMPEROR-Preserved Trial Investigators. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385:1451-1461. [RCA] [PubMed] [DOI] [Full Text] [Cited in This Article: ] [Cited by in Crossref: 1192] [Cited by in RCA: 2515] [Article Influence: 628.8] [Reference Citation Analysis (0)] |
9. | Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, McMurray JJV, Solomon SD. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400:757-767. [RCA] [PubMed] [DOI] [Full Text] [Cited in This Article: ] [Cited by in Crossref: 89] [Cited by in RCA: 442] [Article Influence: 147.3] [Reference Citation Analysis (0)] |
10. | Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, Ferreira JP, Nassif ME, Psotka MA, Tromp J, Borleffs CJW, Ma C, Comin-Colet J, Fu M, Janssens SP, Kiss RG, Mentz RJ, Sakata Y, Schirmer H, Schou M, Schulze PC, Spinarova L, Volterrani M, Wranicz JK, Zeymer U, Zieroth S, Brueckmann M, Blatchford JP, Salsali A, Ponikowski P. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28:568-574. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited in This Article: ] [Cited by in Crossref: 64] [Cited by in RCA: 464] [Article Influence: 154.7] [Reference Citation Analysis (0)] |
11. | McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Skibelund AK; ESC Scientific Document Group. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44:3627-3639. [RCA] [PubMed] [DOI] [Full Text] [Cited in This Article: ] [Cited by in Crossref: 37] [Cited by in RCA: 707] [Article Influence: 353.5] [Reference Citation Analysis (0)] |
12. | Duan XY, Liu SY, Yin DG. Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials. Medicine (Baltimore). 2021;100:e26431. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited in This Article: ] [Cited by in Crossref: 10] [Cited by in RCA: 12] [Article Influence: 3.0] [Reference Citation Analysis (0)] |
13. | Kanai M, Kimura K, Motoki H, Suzuki S, Okano T, Minamisawa M, Yoshie K, Kato T, Saigusa T, Ebisawa S, Okada A, Kuwahara K. Cardio-renal protective effects of SGLT2 inhibitors in patients with type 2 diabetes mellitus and severely impaired renal function. Eur Heart J. 2021;42. [RCA] [DOI] [Full Text] [Cited in This Article: ] [Reference Citation Analysis (0)] |
14. | Liu J, Li L, Li S, Wang Y, Qin X, Deng K, Liu Y, Zou K, Sun X. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2020;22:1619-1627. [RCA] [PubMed] [DOI] [Full Text] [Cited in This Article: ] [Cited by in Crossref: 56] [Cited by in RCA: 97] [Article Influence: 19.4] [Reference Citation Analysis (0)] |
15. | Ikonomidis I, Pavlidis G, Thymis J, Birba D, Kalogeris A, Kousathana F, Kountouri A, Balampanis K, Parissis J, Andreadou I, Katogiannis K, Dimitriadis G, Bamias A, Iliodromitis E, Lambadiari V. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment. J Am Heart Assoc. 2020;9:e015716. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited in This Article: ] [Cited by in Crossref: 60] [Cited by in RCA: 115] [Article Influence: 23.0] [Reference Citation Analysis (0)] |
16. | Brown A, Gandy S, Mccrimmon R, Struthers A, Lang C. Dapagliflozin improves left ventricular myocardial longitudinal function in people with type 2 diabetes. Eur Heart J. 2020;41. [RCA] [DOI] [Full Text] [Cited in This Article: ] [Reference Citation Analysis (0)] |